Different Initial Insulin Dose Regimens on Time to Achieve Glycemic Targets and Treatment Safety in SIIT
8. oktober 2021 oppdatert av: Yanbing Li, Sun Yat-sen University
The Impact of Different Initial Insulin Dose Regimens on Time to Achieve Glycemic Targets and Treatment Safety in Short-term Intensive Insulin Therapy(SIIT)
To compare the effects of different initial insulin dose regimens during the short-term insulin intensive treatment on time to glycemic goal, hypoglycemia prevalence, glycemic variability and other safety problems in newly diagnosed type 2 diabetes mellitus(T2DM) patients, in order to investigate the rational of formula based initiation regimen.
Studieoversikt
Status
Rekruttering
Forhold
Detaljert beskrivelse
Diabetes has become one of the major chronic non-communicable diseases.
Its prevalence was rising in these years.
Short-term intensive insulin therapy can improve the β-cell function and nearly half of the patients can live with long-term glycemic remission.
It has therefore become the recommended treatment for the newly diagnosis T2DM patients with high blood glucose.
However, due to the glycemic goal for intensive therapy is strict, it's important to find out a suitable initial insulin regimen for continuous subcutaneous insulin infusion(CSII) with which patients can achieve euglycemia safely, stably and rapidly.
In previous study, the investigators found out that the total daily insulin dose at the first day when euglycemia was achieved（TDD-1） was associated with weight, waist circumference, triglycerides and fasting blood glucose levels.
According to this, the investigators figured out a formula for estimation of insulin dose for the short-term intensive insulin therapy in patients with newly diagnosed T2DM.
However, its feasibility needs to be further verified.
Therefore, the investigators conducted this prospective randomized controlled study to compare the effects of different initial insulin dose regimens during the short-term insulin intensive treatment on time to glycemic goal, hypoglycemia prevalence, glycemic variability and other safety problems in newly diagnosed type 2 diabetes patients, in order to investigate the rational of formula based initiation regimen.
Studietype
Intervensjonell
Registrering (Forventet)
56
Fase
- Fase 4
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Xinwei Huang, MA
- Telefonnummer: +8613480264781
- E-post: 17301500@qq.com
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510080
- Rekruttering
- endocrinology department of the first affiliated hospital of Sun Yat-sen University
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
20 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Newly diagnosed type 2 diabetes (1999 World Health Organization standard);
- Type 2 diabetic patients who have never received any hypoglycemic therapy (including oral hypoglycemic agents, Chinese medicine , and insulin);
- Body mass index (BMI) between 20-35 kg/m2;
- Fasting plasma glucose (FPG) levels between 7.0 -16.7 mmol/L, glycated haemoglobin >7.0%;
- Willing to receive CSII intensive treatment during hospitalization and monitoring blood glucose 8 times per day.
Exclusion Criteria:
- Type 1 diabetes or special type of diabetes;
- Acute complications of diabetes: ketoacidosis, hyperosmolar coma, lactic acidosis, etc.;
- Severe macrovascular complications: acute cerebral vascular accidents, acute coronary syndromes, peripheral arterial disease requiring vascular intervention or amputees for hospitalization occur within 12 months before selection;
- Severe microvascular complications: proliferative phase retinopathy; urinary albumin excretion rate(AER)> 300 mg/g or urinary protein Positive, quantitative> 0.5 g/d; uncontrolled painful diabetic neuropathy and significant diabetic autonomic neuropathy;
- Obvious liver and kidney dysfunction: alanine aminotransferase ≥ 2.5 times the upper limit of normal, total bilirubin ≥ 1.5 times the upper limit of normal, serum creatinine greater than 150 umol/L or creatinine clearance less than 50 mL/min;
- Significant increase in blood pressure: blood pressure continued to be higher than 180/110 mmHg;
- Significant anemia: hemoglobin <100g /L may require regular blood transfusions;
- Use of drugs that may affect blood glucose during 12 weeks, such as oral/intravenous corticosteroids, growth hormone, estrogen/progestogen, high-dose diuretics, antipsychotics, etc. Low-dose diuretics for antihypertensive purposes (hydrochlorothiazide <25 mg/d, indapamide ≤ 1.5 mg/d), and physiological quantities of thyroid hormones used for replacement therapy are not limited to this;
- Effects associated with other underlying diseases influenced the observation of blood glucose, such as systemic infection or severe comorbidity, malignancy or chronic diarrhea, uncontrolled endocrine gland function abnormalities, chronic cardiac insufficiency (grade III and above), psychosis, or pregnant;
- The patients does not cooperate, or the investigator judges that it may be difficult to complete the study.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Formula-based
Initial insulin regimen was decided according to the formula developed by the investigators previously.
|
Initial total daily insulin dose(TDD) for CSII was calculated with a formula :（estimate TDD-1(eTDD-1) = 0.35× body weight (kg) + 2.05× FPG (mmol/L) + 4.24×triglyceride(mmol/L) + 0.55× waist circumference (cm) - 49.1）, 42% of which was assigned as total basal dose and 58% as total premeal dose, with the pre-meal doses divided into 30:35:35 for breakfast, lunch and dinner.
Andre navn:
|
|
Placebo komparator: Weight-based
Initial insulin regimen was decided according to current guidelines.
|
TDD for CSII was started with 0.5 IU/kg, 50% of which was assigned as total basal dose and 50% as total premeal dose, and the total pre-meal dose was divided equally before each meal.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The time to glycemic goal
Tidsramme: 1 year
|
After CSII begin, the time(days) to reach glycemic goal of each patients.
The glycemic goal defined as at least six out of eight-point fingertip blood glucose meet the standard that fasting blood glucose(FBG) or non-postprandial blood glucose is between 4.4-6.0
mmol/L and 2h postprandial blood glucose(PBG) is between 4.4-8.0
mmol/L.
|
1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of hypoglycemia
Tidsramme: 1 year
|
Differences in incidence of hypoglycemia among treatment arms at the end of study.
|
1 year
|
|
Change of blood glucose fluctuations
Tidsramme: 1 year
|
Differences in blood glucose fluctuations among treatment arms at the end of study.
|
1 year
|
|
Change of β cell function
Tidsramme: 1 year
|
Differences in β-cell indicators among treatment arms at the end of study.
|
1 year
|
|
Change of insulin sensitivity
Tidsramme: 1 year
|
Differences in insulin sensitivity indicators among treatment arms at the end of study.
|
1 year
|
|
Change of insulin dosage
Tidsramme: 1 year
|
Differences in insulin dosage among treatment arms at the end of study.
|
1 year
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Yanbing Li, MD,PhD, endocrinology department of the first affiliated hospital of Sun Yat-sen University
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Forventet)
1. november 2021
Primær fullføring (Forventet)
1. oktober 2022
Studiet fullført (Forventet)
1. oktober 2022
Datoer for studieregistrering
Først innsendt
26. september 2021
Først innsendt som oppfylte QC-kriteriene
8. oktober 2021
Først lagt ut (Faktiske)
19. oktober 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
19. oktober 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
8. oktober 2021
Sist bekreftet
1. oktober 2021
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2021526
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Ubestemt
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .